Group 1 - The core viewpoint of the article is the announcement of the revised Implementation Regulations of the Drug Administration Law of the People's Republic of China, which will take effect on May 15, 2026, aimed at enhancing drug research, registration, production, and safety management [1][2][3] Group 2 - The revised regulations include improvements in drug research and registration systems, supporting clinical value-oriented drug innovation, and establishing accelerated drug registration procedures [1] - The regulations strengthen drug production management by clarifying responsibilities for drug license holders during contract manufacturing and specifying management requirements for traditional Chinese medicine [1] - The regulations also standardize drug operation and usage, enhancing online drug sales management and ensuring the quality of drugs used in medical institutions [1] - Strict drug safety supervision measures are outlined, including detailed quality inspection processes and legal responsibilities for violations [2]
李强签署国务院令 公布修订后的《中华人民共和国药品管理法实施条例》
Xin Hua She·2026-01-27 09:03